



GENENTECH

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Hsei et al. ) Group Art Unit 1644  
Appl. No. : 09/234,182 )  
Filed : January 20, 1999 )  
For : ANTIBODY FRAGMENT- )  
POLYMER CONJUGATES )  
AND HUMANIZED ANTI-IL-8 )  
MONOCLONAL ANTIBODIES )  
Examiner : ROARK, JESSICA H. )

Hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: United States Patent and Trademark Office, P.O. Box 2327, Arlington, VA 22202, on  
October 17, 2002  
(Date)  
Ginger R. Dreger, Reg. No. 33,055

AMENDMENT AND RESPONSE TO OFFICE ACTION

United States Patent and Trademark Office  
P.O. Box 2327  
Arlington, VA 22202

RECEIVED

TECH CENTER 1800-2900

Dear Sir:

In response to the Office Action, mailed on May 20, 2002 (Paper No. 23), setting a three-months term, please consider the following remarks and amendments.

In the Specification:

Please amend the title to read as follows:

~~ANTIBODY FRAGMENT-POLYMER CONJUGATES~~

Please amend the paragraph beginning at page 206, line 1, with following new paragraph:

--Production of a F(ab')<sub>2</sub> version of the humanized anti-IL-8 6G4V11N35A Fab was accomplished by constructing a fusion protein with the yeast GCN4 leucine zipper. The expression plasmid p6G4V11N35A.F(ab')<sub>2</sub> was made by digesting the plasmid p6G425chim2.fab2 with the restriction enzymes bsal and apal to remove the DNA sequence encoding the 6G4.2.5 murine-human chimeric Fab and replacing it with a 2620bp bsal-apal